BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hypertension readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Hypertension\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07297797-564@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-9563: Phase 2 readout est. (NCT07297797)
DESCRIPTION:HRS-9563\, phase 2\, Hypertension.\nStudy: Phase II Clinical St
 udy of HRS-9563 in Patients With Mild to Moderate Hypertension\nEstimated 
 primary completion: December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/hrs-9563#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07297797
URL:https://assetmemo.bio/drug/hrs-9563#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489612-573@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:QLS1410: Phase 2 readout est. (NCT07489612)
DESCRIPTION:QLS1410\, phase 2\, Hypertension.\nStudy: QLS1410 in Participan
 ts With Uncontrolled Hypertension\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/qls1410#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07489612
URL:https://assetmemo.bio/drug/qls1410#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511361-531@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tonlamarsen: Phase 2 readout est. (NCT07511361)
DESCRIPTION:Tonlamarsen\, phase 2\, Hypertension.\nStudy: Study of Efficacy
  and Safety of Tonlamarsen in Participants With a Recent Hospitalization a
 nd a Concurrent Episode of Acute Severe Hypertension\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tonlamarsen#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07511361
URL:https://assetmemo.bio/drug/tonlamarsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222917-525@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Baxfendy (Baxdrostat): Phase 2 readout est. (NCT07222917)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 2\, Hypertension.\nStudy: A Phase
  IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Bax
 drostat Compared With Baxdrostat on Albuminuria in Participants With Chron
 ic Kidney Disease and High Blood Pressure.\nEstimated primary completion: 
 10 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bax
 drostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07222917
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04971720-528@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Entresto (Sacubitril/valsartan): Phase 2/3 readout est. (NCT0497172
 0)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 2/3\, Hypertension.\nSt
 udy: PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP R
 hythm Axis\nEstimated primary completion: 1 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04971720
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07142356-579@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:RTN-001: Phase 2 readout est. (NCT07142356)
DESCRIPTION:RTN-001\, phase 2\, Hypertension.\nStudy: A Study of Modified R
 elease RTN-001 In Patients With Uncontrolled Hypertension\nEstimated prima
 ry completion: March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/rtn-001#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07142356
URL:https://assetmemo.bio/drug/rtn-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654140-944@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:SAL0140: Phase 2 readout est. (NCT07654140)
DESCRIPTION:SAL0140\, phase 2\, Hypertension.\nStudy: A Phase II Clinical T
 rial of Efficacy and Safety of SAL0140 at Different Doses in Patients With
  Uncontrolled Hypertension\nEstimated primary completion: 1 March 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sal0140#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07654140
URL:https://assetmemo.bio/drug/sal0140#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948422-117@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06948422)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol for Orforglipron (LY3502970) in Participants With Hypertension and
  Obesity or Overweight: (ATTAIN-Hypertension Screening)\nEstimated primary
  completion: September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06948422
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948435-117@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06948435)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol Study of Orforglipron (LY3502970) in Participants With Hypertensio
 n and Obesity or Overweight (ATTAIN-Hypertension) GZL1\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06948435
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06952530-117@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06952530)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol Study of Orforglipron (LY3502970) in Participants With Hypertensio
 n and Obesity or Overweight (ATTAIN-Hypertension) GZL2\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/orforglipron#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06952530
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07927556-573@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:QLS1410: Phase 2 readout est. (NCT07927556)
DESCRIPTION:QLS1410\, phase 2\, Hypertension.\nStudy: A Phase II Clinical T
 rial to Evaluate the Efficacy and Safety of QLS1410 Tablets in Patients Wi
 th Uncontrolled Hypertension Who Are Receiving One or More Background Drug
  Treatments\nEstimated primary completion: December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/qls1410#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07927556
URL:https://assetmemo.bio/drug/qls1410#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07833098-578@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:VB19055: Phase 2 readout est. (NCT07833098)
DESCRIPTION:VB19055\, phase 2\, Hypertension.\nStudy: A Phase II Study of V
 B19055 in Uncontrolled or Resistant Hypertension\nEstimated primary comple
 tion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 vb19055#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07833098
URL:https://assetmemo.bio/drug/vb19055#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528027-186@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Safiglipron (HRS-7535): Phase 3 readout est. (NCT07528027)
DESCRIPTION:Safiglipron (HRS-7535)\, phase 3\, Obesity.\nStudy: Phase III S
 tudy of HRS-7535 for Hypertension With Overweight or Obesity\nEstimated pr
 imary completion: December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/safiglipron-hrs-7535#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07528027
URL:https://assetmemo.bio/drug/safiglipron-hrs-7535#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07261098-528@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Entresto (Sacubitril/valsartan): Phase 2 readout est. (NCT07261098)
DESCRIPTION:Entresto (Sacubitril/valsartan)\, phase 2\, Hypertension.\nStud
 y: The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer 
 With Concurrent Hypertension\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sacubitril-valsar
 tan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07261098
URL:https://assetmemo.bio/drug/sacubitril-valsartan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686120-525@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20280209
DTEND;VALUE=DATE:20280210
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT07686120)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participant
 s With Uncontrolled Hypertension.\nEstimated primary completion: 9 Februar
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/baxdrostat#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076861
 20
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268873-525@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT06268873)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  III Study to Investigate the Efficacy and Safety of Baxdrostat in Combina
 tion With Dapagliflozin on CKD Progression in Participants With CKD and Hi
 gh Blood Pressure.\nEstimated primary completion: 24 February 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/baxdrostat#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06268873
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07368608-557@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:BEBT-701: Phase 1/2 readout est. (NCT07368608)
DESCRIPTION:BEBT-701\, phase 1/2\, Hypertension.\nStudy: A Study of BEBT-70
 1 in Patients With Mild to Moderate Hypertension and Elevated Low-Density 
 Lipoprotein Cholesterol（LDL-C）\nEstimated primary completion: 30 Novem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bebt-701#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073686
 08
URL:https://assetmemo.bio/drug/bebt-701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352969-533@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20290327
DTEND;VALUE=DATE:20290328
SUMMARY:IBI3016: Phase 2 readout est. (NCT07352969)
DESCRIPTION:IBI3016\, phase 2\, Hypertension.\nStudy: A Dose Finding Study 
 of IBI3016 in Mild to Moderate Hypertensive Patients\nEstimated primary co
 mpletion: 27 March 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ibi3016#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07352969
URL:https://assetmemo.bio/drug/ibi3016#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07794579-117@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07794579)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron in Participants With Overweight at Risk of Development of Ob
 esity-Related Complications or Progression to Class 1 Obesity\nEstimated p
 rimary completion: August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/orforglipron#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07794579
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07064473-369@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20291214
DTEND;VALUE=DATE:20291215
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT07064473)
DESCRIPTION:Vicadrostat\, phase 3\, Type 2 Diabetes.\nStudy: EASi-PROTKT™
  - A Study to Test Vicadrostat (BI 690517) Taken Together With Empaglifloz
 in in People With Type 2 Diabetes\, High Blood Pressure\, and Cardiovascul
 ar Disease\nEstimated primary completion: 14 December 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/vicadrostat#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07064473
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742723-525@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Baxfendy (Baxdrostat): Phase 3 readout est. (NCT06742723)
DESCRIPTION:Baxfendy (Baxdrostat)\, phase 3\, Hypertension.\nStudy: A Phase
  III Renal Outcomes and Cardiovascular Mortality Study to Investigate the 
 Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Par
 ticipants With Chronic Kidney Disease and High Blood Pressure\nEstimated p
 rimary completion: 18 December 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/baxdrostat#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06742723
URL:https://assetmemo.bio/drug/baxdrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181109-532@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20300923
DTEND;VALUE=DATE:20300924
SUMMARY:Zilebesiran: Phase 3 readout est. (NCT07181109)
DESCRIPTION:Zilebesiran\, phase 3\, Hypertension.\nStudy: Zilebesiran in Pa
 tients With Hypertension Not Adequately Controlled and With Either Establi
 shed Cardiovascular Disease or High Risk for Cardiovascular Disease\nEstim
 ated primary completion: 23 September 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/zilebesiran#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07181109
URL:https://assetmemo.bio/drug/zilebesiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543120-11268@assetmemo.bio
DTSTAMP:20261121T004032Z
DTSTART;VALUE=DATE:20310507
DTEND;VALUE=DATE:20310508
SUMMARY:QCZ484: Phase 2 readout est. (NCT07543120)
DESCRIPTION:QCZ484\, phase 2\, Hypertension.\nStudy: An Open-label Extensio
 n Safety and Efficacy Study of QCZ484 in Hypertensive Patients.\nEstimated
  primary completion: 7 May 2031. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/qcz484#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07543120
URL:https://assetmemo.bio/drug/qcz484#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
